AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study with an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510888-39-00

Acronym

BAN2401-G000-303

Enrollment

Registered

2024-06-06

Start date

2021-07-21

Completion date

Unknown

Last updated

2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preclinical Alzheimer’s Disease and Elevated Amyloid, Early Preclinical Alzheimer’s Disease and Intermediate Amyloid

Brief summary

A45 Trial: Change from baseline in PACC5 at 216 weeks., A3 Trial: Change from baseline in amyloid PET SUVr at 216 weeks.

Detailed description

A45 Trial: Change from baseline in amyloid PET SUVr at 96 and 216 weeks, A45 Trial: Change from baseline in tau PET SUVr at 96 and 216 weeks, A45 Trial: Change from baseline in CFI at 216 weeks, A3 Trial: Change from baseline in tau PET SUVr at 216 weeks

Interventions

DRUGLECANEMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
A45 Trial: Change from baseline in PACC5 at 216 weeks., A3 Trial: Change from baseline in amyloid PET SUVr at 216 weeks.	—

Secondary

Measure	Time frame
A45 Trial: Change from baseline in amyloid PET SUVr at 96 and 216 weeks, A45 Trial: Change from baseline in tau PET SUVr at 96 and 216 weeks, A45 Trial: Change from baseline in CFI at 216 weeks, A3 Trial: Change from baseline in tau PET SUVr at 216 weeks	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026